BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1810 related articles for article (PubMed ID: 32592501)

  • 1. The cytokine storm and COVID-19.
    Hu B; Huang S; Yin L
    J Med Virol; 2021 Jan; 93(1):250-256. PubMed ID: 32592501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
    Shawki MA; Elsayed NS; Mantawy EM; Said RS
    Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
    Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.
    Pum A; Ennemoser M; Adage T; Kungl AJ
    Biomolecules; 2021 Jan; 11(1):. PubMed ID: 33445810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions.
    Asrani P; Hassan MI
    Mol Cell Biochem; 2021 Feb; 476(2):675-687. PubMed ID: 33064288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.
    Song N; Wakimoto H; Rossignoli F; Bhere D; Ciccocioppo R; Chen KS; Khalsa JK; Mastrolia I; Samarelli AV; Dominici M; Shah K
    Stem Cells; 2021 Jun; 39(6):707-722. PubMed ID: 33586320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sEH inhibition on the eicosanoid and cytokine storms in SARS-CoV-2-infected mice.
    Edin ML; Gruzdev A; Graves JP; Lih FB; Morisseau C; Ward JM; Hammock BD; Bosio CM; Zeldin DC
    FASEB J; 2024 May; 38(10):e23692. PubMed ID: 38786655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunopathogenesis and treatment of cytokine storm in COVID-19.
    Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
    Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.
    Chen R; Lan Z; Ye J; Pang L; Liu Y; Wu W; Qin X; Guo Y; Zhang P
    Front Immunol; 2021; 12():589095. PubMed ID: 33995341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.
    Hafezi B; Chan L; Knapp JP; Karimi N; Alizadeh K; Mehrani Y; Bridle BW; Karimi K
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm.
    Peng X; Wang Y; Xi X; Jia Y; Tian J; Yu B; Tian J
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):231-247. PubMed ID: 33404925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm.
    Gangemi S; Tonacci A
    Cytokine Growth Factor Rev; 2021 Apr; 58():111-113. PubMed ID: 32938545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome.
    Rossi M; Piagnerelli M; Van Meerhaeghe A; Zouaoui Boudjeltia K
    Med Hypotheses; 2020 Nov; 144():110242. PubMed ID: 33254548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Impaired Inflammatory and Innate Immune Response in COVID-19.
    Park SH
    Mol Cells; 2021 Jun; 44(6):384-391. PubMed ID: 34098591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence.
    Mohanty RR; Padhy BM; Das S; Meher BR
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2802-2807. PubMed ID: 33829465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of HMGB1 in COVID-19-induced cytokine storm and its potential therapeutic targets: A review.
    Wulandari S; Hartono ; Wibawa T
    Immunology; 2023 Jun; 169(2):117-131. PubMed ID: 36571562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of Covid-19 cytokine storm by tocilizumab.
    Boretti A; Banik B
    J Med Virol; 2022 Mar; 94(3):823-828. PubMed ID: 34617604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
    Quirch M; Lee J; Rehman S
    J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Role of Colchicine in Combating COVID-19 Cytokine Storm and Its Ability to Inhibit Protease Enzyme of SARS-CoV-2 as Conferred by Molecular Docking Analysis.
    Kamel NA; Ismail NSM; Yahia IS; Aboshanab KM
    Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.